ViroLogic Promoting PhenoSense HIV Drug Susceptibility Test To Physicians
This article was originally published in The Gray Sheet
Executive Summary
Sales reps from ViroLogic, Inc. began calling physicians across the U.S. on Nov. 15 to promote the company's recently commercialized phenotypic HIV drug susceptibility assay, PhenoSense HIV.
You may also be interested in...
Gilead Sales Reps To Promote Virco HIV Resistance Test Services
Gilead Sciences will leverage its 60-rep U.S. sales force under a collaborative promotional and educational effort with Virco to increase awareness among physicians treating patients with HIV of Virco's phenotypic and genotypic HIV resistance monitoring assays, the firms announced March 7.
Gilead Sales Reps To Promote Virco HIV Resistance Test Services
Gilead Sciences will leverage its 60-rep U.S. sales force under a collaborative promotional and educational effort with Virco to increase awareness among physicians treating patients with HIV of Virco's phenotypic and genotypic HIV resistance monitoring assays, the firms announced March 7.
ViroLogic, Inc.
Proposed initial public offering valued at up to $75 mil. is outlined in a preliminary prospectus filed Feb. 22 with the Securities and Exchange Commission. The South San Francisco biotechnology firm's first product, the PhenoSense HIV phenotypic test to directly and quantitatively measure resistance of a patient's HIV to antiviral drugs in order to facilitate appropriate drug selection, commenced active marketing in November 1999 (1"The Gray Sheet" Nov. 22, p. 15). The company is also developing PhenoSense products for other viral diseases, including hepatitis B and C. Proceeds from the IPO will be used to expand sales and marketing activities and for various capital expenditures, including clinical laboratory expansion. CIBC World Markets Corp. is lead manager of the offering; ING Barings and Prudential Vector Healthcare Group are co-managers